PTC THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.52 USD | +9.70% |
|
+1.98% | +32.51% |
| 06-21 | BofA Securities Adjusts PTC Therapeutics Price Target to $32 From $25, Maintains Underperform Rating | MT |
| 06-20 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,960 | 4,164 | 2,816 | 2,786 | 2,080 | 2,801 | - | - |
| Enterprise Value (EV) 1 | 2,986 | 3,393 | 2,474 | 2,947 | 1,487 | 2,289 | 2,406 | 2,274 |
| P/E ratio | -11.2 x | -9.19 x | -5.36 x | -4.9 x | -3.29 x | -7.26 x | -12.9 x | -52.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9.64 x | 10.9 x | 5.23 x | 3.99 x | 2.22 x | 3.72 x | 3.32 x | 2.97 x |
| EV / Revenue | 9.73 x | 8.91 x | 4.59 x | 4.22 x | 1.59 x | 3.04 x | 2.85 x | 2.41 x |
| EV / EBITDA | - | -12 x | -7.97 x | -9.25 x | -7.33 x | -52.7 x | 19.2 x | 13.2 x |
| EV / FCF | -26.6 x | -16 x | -8.85 x | -7.58 x | -7.96 x | -41.6 x | 27.3 x | 9.1 x |
| FCF Yield | -3.76% | -6.25% | -11.3% | -13.2% | -12.6% | -2.4% | 3.66% | 11% |
| Price to Book | 5.01 x | 8.36 x | 1,952 x | -7.89 x | -2.55 x | -2.77 x | -2.8 x | -3.25 x |
| Nbr of stocks (in thousands) | 61,631 | 68,236 | 70,698 | 72,991 | 75,463 | 76,697 | - | - |
| Reference price 2 | 48.03 | 61.03 | 39.83 | 38.17 | 27.56 | 36.52 | 36.52 | 36.52 |
| Announcement Date | 02/03/20 | 25/02/21 | 22/02/22 | 21/02/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 307 | 380.8 | 538.6 | 698.8 | 937.8 | 752.1 | 843 | 942.6 |
| EBITDA 1 | - | -282.7 | -310.3 | -318.6 | -202.9 | -43.44 | 125.5 | 172.3 |
| EBIT 1 | -241.2 | -326.2 | -374.4 | -447.4 | -439.5 | -216.7 | -26.94 | 85.6 |
| Operating Margin | -78.56% | -85.66% | -69.52% | -64.03% | -46.86% | -28.82% | -3.2% | 9.08% |
| Earnings before Tax (EBT) 1 | -239.9 | -402.9 | -518.3 | -587.5 | -696.1 | -394.7 | -241.2 | -65.5 |
| Net income 1 | -251.6 | -438.2 | -523.9 | -559 | -626.6 | -382.3 | -202.9 | -57.13 |
| Net margin | -81.95% | -115.07% | -97.27% | -80% | -66.81% | -50.84% | -24.07% | -6.06% |
| EPS 2 | -4.270 | -6.640 | -7.430 | -7.790 | -8.370 | -5.028 | -2.833 | -0.6904 |
| Free Cash Flow 1 | -112.4 | -211.9 | -279.5 | -388.7 | -186.9 | -55 | 88 | 250 |
| FCF margin | -36.61% | -55.65% | -51.9% | -55.62% | -19.92% | -7.31% | 10.44% | 26.52% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 70.1% | 145.13% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 02/03/20 | 25/02/21 | 22/02/22 | 21/02/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 165.2 | 148.7 | 165.5 | 217.1 | 167.4 | 220.4 | 213.8 | 196.6 | 307.1 | 210.1 | 183.7 | 168.4 | 193 | 135 | 197.6 |
| EBITDA | - | -60.21 | - | - | - | -74.79 | -158.5 | - | 86.52 | - | - | - | - | - | - |
| EBIT 1 | -84.73 | -86.52 | -92.36 | -68.19 | -200.3 | -117.6 | -209.5 | -118.2 | 5.82 | -45.45 | -48.69 | -72.82 | -47.14 | -41.08 | 22.8 |
| Operating Margin | -51.28% | -58.17% | -55.8% | -31.4% | -119.67% | -53.37% | -98.01% | -60.11% | 1.9% | -21.63% | -26.5% | -43.25% | -24.43% | -30.43% | 11.54% |
| Earnings before Tax (EBT) 1 | -138.6 | -121.9 | -148.7 | -127.2 | -189.7 | -135 | -237.5 | -166.6 | -157.1 | -84.7 | -88.44 | -119.1 | -101.2 | - | - |
| Net income 1 | -143.3 | -126.7 | -152.1 | -109.3 | -170.9 | -139 | -198.9 | -133 | -155.8 | -91.58 | -85.38 | -110.7 | -96.95 | -39.3 | -7.7 |
| Net margin | -86.71% | -85.2% | -91.88% | -50.35% | -102.08% | -63.05% | -93.02% | -67.64% | -50.74% | -43.58% | -46.47% | -65.72% | -50.24% | -29.11% | -3.9% |
| EPS 2 | -2.030 | -1.780 | -2.130 | -1.530 | -2.350 | -1.880 | -2.660 | -1.760 | -2.060 | -1.200 | -1.071 | -1.451 | -1.418 | -1.143 | -0.6900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22/02/22 | 03/05/22 | 04/08/22 | 27/10/22 | 21/02/23 | 27/04/23 | 03/08/23 | 26/10/23 | 29/02/24 | 25/04/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 25.8 | - | - | 161 | - | - | - | - |
| Net Cash position 1 | - | 771 | 342 | - | 593 | 512 | 395 | 527 |
| Leverage (Debt/EBITDA) | - | - | - | -0.5054 x | - | - | - | - |
| Free Cash Flow 1 | -112 | -212 | -280 | -389 | -187 | -55 | 88 | 250 |
| ROE (net income / shareholders' equity) | -53.2% | -81.4% | -217% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -18.3% | -22.9% | -25.3% | -30.7% | -23.4% | -22.8% | -4.4% | 22.1% |
| Assets 1 | 1,372 | 1,916 | 2,073 | 1,822 | 2,676 | 1,677 | 4,611 | -258.5 |
| Book Value Per Share 2 | 9.600 | 7.300 | 0.0200 | -4.840 | -10.80 | -13.20 | -13.10 | -11.20 |
| Cash Flow per Share 2 | -1.680 | -2.940 | -3.570 | -4.970 | -2.120 | -2.000 | -1.060 | - |
| Capex 1 | 13.8 | 17.8 | 28.2 | 32 | 28.4 | 27 | 33.7 | 29 |
| Capex / Sales | 4.48% | 4.69% | 5.24% | 4.58% | 3.03% | 3.59% | 3.99% | 3.08% |
| Announcement Date | 02/03/20 | 25/02/21 | 22/02/22 | 21/02/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
36.52
USD
Average target price
38.17
USD
Spread / Average Target
+4.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.51% | 2.8B | |
| +15.19% | 121B | |
| +19.91% | 114B | |
| +18.14% | 23.61B | |
| -19.80% | 20.43B | |
| -15.59% | 16.55B | |
| -13.45% | 16.45B | |
| -44.35% | 15.59B | |
| +66.67% | 15.19B | |
| +2.13% | 13.54B |
- Stock Market
- Equities
- PTCT Stock
- Financials PTC Therapeutics, Inc.
